Treatment of children with acute promyelocytic leukemia: results of the first North American Intergroup trial INT0129.

ABSTRACT:

Background

This report focuses on the children enrolled on the first North American Intergroup study of APL (INT0129). This study was designed to compare the rates of CR, disease-free survival (DFS), overall survival (OS) and toxicity of therapy with all-trans-retinoic acid (ATRA) for remission induction and/or maintenance compared to conventional chemotherapy in patients with previously untreated APL.

Procedure

Fifty-three patients who were documented to have the t(15;17) translocation were able to be evaluated for toxicity of treatment, outcome of induction, and survival.

Results

The overall CR rate was 81%. The estimated 5-year DFS from time of CR was 41% for all patients. The estimated 5-year OS for all patients from entry into the study was 69%. The 5-year DFS fr

SUBMITTER: Gregory J 

PROVIDER: S-EPMC3508725 | biostudies-literature | 2009 Dec

REPOSITORIES: biostudies-literature